May 22, 2014 – Alectos today announced publication of preclinical studies showing that both knockdown and pharmacological inhibition of O-GlcNAc transferase (OGT) result in reduced metabolic output, increased apoptosis, and impaired survival in tumor cells.  This data strongly supports OGT as a novel cancer metabolism target.

For details, see: Ferrer, C.M. et al. Mol Cell 54, 820-31 (2014).